Zacks Gives Neutral Rating to Boston Scientific (BSX)

By admin | 7 years ago

Boston Scientific (NYSE: BSX)‘s stock had its “neutral” rating restated by Zacks in a report issued on Tuesday. They currently have a $6.75 target price on the stock.

Shares of Boston Scientific opened at 6.22 on Tuesday. Boston Scientific has a one year low of $5.01 and a one year high of $7.55. The company has a market cap of $8.890 billion and a P/E ratio of 18.24.

Boston Scientific last issued its quarterly earnings data on Thursday, April 19th. The company reported $0.15 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.13 by $0.02. The company’s quarterly revenue was down 3.1% on a year-over-year basis. On average, analysts predict that Boston Scientific will post $0.11 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at Barclays Capital (NYSE: BCS) reiterated an “underweight” rating on shares of Boston Scientific in a research note to investors on Tuesday, March 20th. Analysts at Northland Securities initiated coverage on shares of Boston Scientific in a research note to investors on Friday, March 2nd. They set an “outperform” rating and a $7.50 price target on the stock.

Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

About the author